Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272603 | 1.00 | PDE2A (0.48) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL22041141 | 0.91 | GPR139 (0.45) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL22952766 | 0.89 | GPR139 (0.44) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL28709108 | 0.89 | GPR139 (0.44) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL29440441 | 0.89 | GPR139 (0.44) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL29589674 | 0.88 | GPR139 (0.45) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL21272729 | 0.88 | GPR139 (0.45) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL21272728 | 0.88 | GPR139 (0.45) | PDE2AGPR139ITGB3ITGAVITGB5 | |
| SCHEMBL21272694 | 0.87 | GPR139 (0.58) | GPR139LMNAPOLB | |
| SCHEMBL21272691 | 0.87 | GPR139 (0.58) | GPR139LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | H. LUNDBECK A/S (DK) | 2025-12-30 | — | — | US | disclosed |
| EP-4007571-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H LUNDBECK AS (DK) | 2025-06-18 | — | — | EP | disclosed |
| EP-4241843-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2025-05-21 | — | — | EP | disclosed |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-20220380300-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2022-12-01 | — | — | US | disclosed |
| US-20220280455-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. LUNDBECK A/S (DK) | 2022-09-08 | — | — | US | disclosed |
| US-11434199-B2 | Alcohol derivatives as KV7 potassium channel openers | H. LUNDBECK A/S (DK) | 2022-09-06 | — | — | US | disclosed |
| EP-4007571-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. Lundbeck A/S (DK) | 2022-06-08 | — | — | EP | disclosed |
| WO-2021023616-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. LUNDBECK A/S (DK) | 2021-02-11 | — | — | WO | disclosed |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2020-06-04 | — | — | US | disclosed |
| US-10590067-B2 | Alcohol derivatives of carboxamides as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2020-03-17 | — | — | US | disclosed |
| WO-2019161877-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-29 | — | — | WO | disclosed |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280455-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | KCNA7, KCNQ5, KCNQ2 | PDE2A 2896/4885GPR139 475/4885ITGB3 2627/4885 |
| US-11434199-B2 | Alcohol derivatives as KV7 potassium channel openers | KCNA7, KCNK17, KCNQ1 | PDE2A 2139/4885GPR139 663/4885ITGB3 2840/4885 |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | PDE2A 2139/4885GPR139 663/4885ITGB3 2840/4885 |
| US-10590067-B2 | Alcohol derivatives of carboxamides as Kv7 potassium channel openers | KCNA7, KCNQ5, KCNQ1 | PDE2A 2249/4885GPR139 480/4885ITGB3 3581/4885 |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | PDE2A 2139/4885GPR139 663/4885ITGB3 2840/4885 |
| US-20220380300-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | PDE2A 2139/4885GPR139 663/4885ITGB3 2840/4885 |
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | KCNN3, KCNN1, KCNN2 | PDE2A 3502/4885GPR139 1311/4885ITGB3 1115/4885 |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | KCNA7, KCNK17, KCNQ1 | PDE2A 2139/4885GPR139 663/4885ITGB3 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.